A comparison of teriparatide and calcitonin therapy in postmenopausal Asian women with osteoporosis: A 6-month study

Current Medical Research and Opinion

Volumn 22, Issue 5, 2006, Pages 929-937

  Kung, A W C ^a   Pasion, E G ^b   Sofiyan, M ^c   Lau, E M C ^d   Tay, B K ^e   Lam, K S ^f   Wilawan, K ^g   Ongphiphadhanakul, B ^h   Thiebaud, Daniel ^i,j  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b Our Lady of Lourdes Hospital   (Philippines)

^c HOSPITAL KUALA LUMPUR   (Malaysia)

^d Hong Kong Orthopaedic and Osteoporosis Center for Treatment and Research   (Hong Kong)

^e SINGAPORE GENERAL HOSPITAL   (Singapore)

^f CHANGI GENERAL HOSPITAL   (Singapore)

^g Royal Thai Army   (Thailand)

^h MAHIDOL UNIVERSITY   (Thailand)

ⁱ ELI LILLY AND COMPANY   (United States)

^j ELI LILLY AUSTRALIA PTY LTD   (Australia)

more..

Author keywords

Asia; Bone mineral density; Calcitonin; Osteoporosis; Teriparatide

Indexed keywords

ALKALINE PHOSPHATASE; CALCITONIN; CALCIUM; OSTEOCALCIN; PARATHYROID HORMONE[1-34]; VITAMIN D;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ASIA; ASIAN; BONE DENSITY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONTUSION; COUGHING; DISEASE ASSOCIATION; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLUSHING; HEADACHE; HIP FRACTURE; HOT FLUSH; HUMAN; INJECTION SITE CONTUSION; LIMB PAIN; MULTICENTER STUDY; MUSCLE CRAMP; NAUSEA; OSTEOPOROSIS; PARESTHESIA; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; RASH; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VITAMIN SUPPLEMENTATION; VOMITING;

AGE FACTORS; AGED; AGED, 80 AND OVER; ASIA, SOUTHEASTERN; ASIAN CONTINENTAL ANCESTRY GROUP; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCITONIN; CHINA; FEMALE; FRACTURES, BONE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RISK ASSESSMENT; RISK FACTORS; TERIPARATIDE; TREATMENT OUTCOME;

EID: 33745036172     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X104768     Document Type: Conference Paper

References (25)

1. Gullberg B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporos Int 1997;7:407-13
2. Divittorio G, Jackson KL, Chindalore VL, et al. Examining the relationship between bone mineral density and fracture risk reduction during pharmacologic treatment of osteoporosis. Pharmacotherapy 2006;26:104-14
3. Kanis JA, Johnell O, Oden, et al. The use of multiple sites for the diagnosis of osteoporosis. Osteoporos Int 2006;10:1-8
4. Riggs BL, Parfitt AM. Drugs used to treat osteoporosis: The critical need for a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res 2005;20:177-84
5. Seeman E, Delmas PD. Reconstructing the skeleton with intermittent parathyroid hormone. Trends Endocrinol Metab 2001;12:281-3
6. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41
7. Quattrocchi E, Kourlas H. Teriparatide: a review. Clin Ther 2004;26:841-54
8. Heaney RP. Advances in therapy for osteoporosis. Clin Med Res 2003;1:93-9
9. Greenblatt D. Treatment of postmenopausal osteoporosis. Pharmacotherapy 2005;25:574-84
10. Body JJ. Calcitonin for the long-term prevention and treatment of postmenopausal osteoporosis. Bone 2002;30:75S-9
11. Chesnut CH III, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000;109:267-76
12. Hwang JS, Tu ST, Yang TS, et al. Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis. Osteoporos Int 2006;17(3) doi:10.1007/s00198-005-2002-5
13. Cummings SR, Chapurlat RD. What PROOF proves about calcitonin and clinical trials. Am J Med 2000;109:330-1
14. McClung MR, San Martin J, Miller PD, et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 2005;165:1762-8
15. Hodsman AB, Fraher LJ, Watson PH, et al. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 1997;82:620-8
16. Ettinger B, San Martin J, Crans G, et al. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004;19:745-51
17. Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003;18:9-17
18. Crandall C. Parathyroid hormone for treatment of osteoporosis. Arch Intern Med 2002;162:2297-309
19. Gennari C, Chierichetti SM, Bigazzi S, et al. Comparative effects on bone mineral content of calcium and calcium plus salmon calcitonin given in two different regimens in postmenopausal osteoporosis. Curr Ther Res 1985;38:455-64
20. Thamsborg G, Storm TL, Sykulski R, et al. Effect of different doses of nasal salmon calcitonin on bone mass. Calcif Tissue Int 1991;48:302-7
21. Overgaard K, Hansen MA, Jensen SB, et al. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 1992;305:556-61
22. O'Doherty DP, Bickerstaff DR, McCloskey EV, et al. A comparison of the acute effects of subcutaneous and intranasal calcitonin. Clin Sci (Lond) 1990;78:215-9
23. Overgaard K, Agnusdei D, Hansen MA, et al. Dose-response bioactivity and bioavailability of salmon calcitonin in pre-menopausal and postmenopausal women. J Clin Endocrinol Metab 1991;72:344-9
24. Chen P, Satterwhite JH, Licata AA, et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 2005;20:962-70
25. Chen P, Miller P, Delmas P, et al. Change in bone mineral density (BMD) and fracture risk reduction in teriparatide-treated women with osteoporosis. J Bone Miner Res 2005;20:S56-7